Introduction
Angiogenesis is the formation of new blood vessels from a preexisting endothelium that involves proliferation of capillary endothelial cells and their migration toward the angiogenic stimulus (Folkman, 1995; Battegay, 1995; Ferrara, 1999; Weidner and Folkman, 1996; Kim et al., 1992) . This process is regulated by endothelial cell mitogens, of which VEGF is a potent angiogenic factor.
A variety of studies have shown the importance of VEGF as a prognostic indicator of the severity of breast cancer. The effect of VEGF-165 on endothelial cells has been shown to be mediated via the receptors Flt-1, Flk-1/KDR, and Neuropilin-1 (Leung et al., 1989; Houck et al., 1991; Tischer et al., 1989; Poltorak et al., 1997; Keyt et al., 1996; Soker et al., 1996 Soker et al., , 1997 Soker et al., , 1998 Shibuya et al., 1990; de Vries et al., 1992; Terman et al., 1992; Waltenberger et al., 1994) . Stimulation of endothelial cells by VEGF-165 resulted in cell proliferation and migration (Waltenberger et al., 1994; Soker et al., 1996 Soker et al., , 1998 Yoshida et al., 1996; Grunstein et al., 1999) . VEGF has been shown to be present in breast tumors at levels that are, on average, sevenfold higher than in normal adjacent tissue (Yoshiji et al., 1996) . A number of studies have shown that VEGF secretion by tumor cells is a prerequisite of tumor development, and that VEGF was required for the initial stages of breast tumorigenesis (Yoshiji et al., 1997; Kranz et al., 1999) . Inhibition of angiogenesis by such agents as angiostatin and endostatin resulted in reduced tumorigenesis and some regression of established tumors (O'Reilly et al., 1994 Boehm et al., 1997; Bergers et al., 1999) . Recently, we showed that VEGF-165 stimulated the invasion of T47D breast cancer cells into Matrigel , and that VEGF required the extracellular matrix components to induce mitogenic effects and migratory response in breast cancer cells ). Moreover, VEGF was shown to be an autocrine survival factor for neuropilin-expressing breast carcinoma cells and its expression was found to be essential for the survival of metastatic breast carcinoma cells (Bachelder et al., 2001) .
VEGF is regulated by estradiol and tamoxifen in the uterus and by estradiol in human breast cancer cells Levine et al., 1998; Santin et al., 1999; Guidi et al., 1995; Gasparini, 1997) . Estrogen rapidly induced expression of VEGF mRNA, and the elevations in VEGF transcript levels were sensitive to inhibitors of RNA but not to protein synthesis (Gasparini, 1997; Hyder et al., 2000; Ali et al., 2000; Hilakivi-Clarke, 2000; Prall et al., 1998; Jordan, 2001) . Recently, functional estrogen response elements (EREs) in the promoter region of the gene coding for VEGF were identified (Hyder et al., 2000) . 17b-estradiol (E 2 ) was found to directly regulate VEGF gene transcription in endometrial cells and in Ishikama adenocarcinoma cells (Ali et al., 2000) . Estradiolinduced gene transcription is ER dependent and is activated through a variant ERE localized *1.5 Kb upstream from the VEGF transcription start site in these cells (Hyder et al., 2000; Ali et al., 2000) . Thus, estrogens may regulate directly VEGF transcription in target tissues and tumors, via a complex interplay of cis-and trans-acting elements.
Estrogenic steroids, including 17b-estradiol (E 2 ), regulate cellular function in a wide variety of tissues and influence proliferation in the female reproductive tract and mammary glands (Hilakivi-Clarke, 2000; Prall et al., 1998; Jordan, 2001) . A role for estrogens in breast cancer etiology is well established and relates to their growth-stimulatory actions. Estrogens elicit proliferative responses in breast cancer cells in vivo and in vitro and are essential for initiation and progression of breast cancer in animal models (Lippman et al., 1976; Sutherland et al., 1983; Osborne et al., 1983; Taylor et al., 1983; Jordan and Murphy, 1990; van der Burg et al., 1988; Foster and Wimalasena, 1996; Altucci et al., 1996) . The estrogen receptors (ERs) are members of the steroid/thyroid hormone and vitamin A/D nuclear receptor superfamily. The members of this family share a common domain structure with distinct functional domains referred to as A to E (F) domains, including the DNA binding domain (C domain), the N-terminal A/B domain (AF-1) and the C-terminal E domain (AF-2). Although both AF-1 and AF-2 are required to achieve maximal transcription activity, only AF-2 activity is completely dependent on ligand binding. In the absence of estrogen, ER is transcriptionally inactive, indicating the AF-1 is suppressed by AF-2.
Hereditary breast cancers are attributed to mutations in the breast cancer susceptibility BRCA1 gene (Miki et al., 1994; Ford et al., 1994; Struewing et al., 1997) . The BRCA1 gene encodes an 1863-amino acid protein with an N-terminal RING finger domain and a Cterminal transcription activation domain (Chen et al., 1999) . BRCA1 is a nuclear phosphoprotein involved in cell proliferation, cell cycle progression, DNA repair and recombination. The BRCA1 gene was also found to inhibit estrogen-dependent transactivation through its direct interaction with ER-a in human breast and prostate cancer cell lines (Fan et al., 1999 (Fan et al., , 2001 . The amino-terminus of BRCA1 (1 -300) was reported to interact with ER-a while the carboxyl-terminus of BRCA1 may function as a transcription repression domain (Fan et al., 2001) . In addition, BRCA1 was reported to mediate the ligand-independent transcription repression of the estrogen receptor (Zheng et al., 2001) .
The role of BRCA1 as a tumor suppressor gene in the estrogen signaling pathway is still largely unknown. Furthermore, the regulation of VEGF gene transcription activation and secretion by BRCA1 is unknown. Herein, we describe a role for BRCA1 in mediating the inhibition of VEGF gene transcription and secretion via the estrogen signaling pathway in breast cancer. These findings suggest a novel potential role for BRCA1 and ER-a in regulating VEGF function in hormone-responsive breast cancer cells.
Results

BRCA1 interacts directly with ER-a in vitro and in vivo in breast cancer cells and in normal breast epithelial cells
To determine whether ER-a directly interacts with BRCA1, a binding assay of BRCA1 with ER-a was performed using 293T cells transiently transfected with HA-tagged BRCA1 and ER-a expression constructs. Total cell lysates were prepared and immunoprecipitated with anti-HA antibody. The immunoprecipitates were analysed by 8% SDS -PAGE followed by Western blot analysis using anti-ER-a antibody. ER-a was found to associate with BRCA1, suggesting that it interacts directly with BRCA1 ( Figure 1a ). Furthermore, when total cell lysates were immunoprecipitated with ER-a specific antibodies and analysed by Western blot analysis using HA-tagged BRCA1 specific antibodies, a specific interaction of BRCA1 with ER-a was also observed (Figure 1a ). To determine if the association of BRCA1 and ER-a was due to a direct physical interaction, we performed glutathione-S-transferase [GST] capture assays using a series of GST-BRCA1 fusion proteins. As shown in Figure 1b , BRCA1 domains 1 -306 and 428 -683 a.a. interacted specifically with ER-a while no interaction was observed with other domains of BRCA1, indicating that ER-a associates with the N-terminus of BRCA1 through two domains: 1 -306 and 428 -683 a.a. Next, we determined the domain of ER-a that binds with BRCA1, using a series of GST-ER proteins ( Figure  1c) . The ER-a-EF (AF-2) domain strongly interacted with BRCA1, indicating that the C-terminus of ER-a was essential for the direct interaction of ER-a with BRCA1 and that BRCA1 directly interacts with the ligand-binding domain (AF-2) of ER-a (Figure 1d) .
To determine whether endogenous interaction between BRCA1 and ER-a is present in breast cancer cells, their possible interaction was analysed in 293T cells transfected with HA-BRCA1 and ER-a cDNA constructs. Strong association of ER-a and BRCA1 was observed in these cells. However, upon stimulation with the ligand-E 2 for 30 min, this association was decreased significantly (Figure 2a) . To analyse the effects of E 2 on the endogenous interaction of ER-a and BRCA1, we used normal MCF-10A breast epithelial cells and MCF-7 breast cancer cells, which were expressing ER-a (ER-a positive cells). Cells were untreated or stimulated with 17b-estradiol (E 2 ) for 30 min, harvested, and lysed. Immunoprecipitations were performed using control or ER-a antibodies, followed by Western blotting with BRCA1 and ER-a antibodies as indicated. A strong endogenous interaction of ER-a with BRCA1 in the absence of E 2 was observed in these cells, and this direct interaction was significantly reduced in the presence of estrogen (Figure 2b ,c). These results indicate that ER-a constitutively interacts with BRCA1 in ER-positive breast cancer cells and breast epithelial cells and that this interaction is down-regulated in the presence of estrogen. 293T cells were transiently transfected with ER-a and HA-BRCA1 cDNA constructs as indicated. After recovery from transfection, the cells were lysed in binding buffer and immunoprecipitated with either anti-HA antibody or anti-ER-a antibody. The immunoprecipitates were analysed by 8% SDS -PAGE followed by Western blot analysis using either anti-ER-a antibody or BRCA1 (HA) specific antibodies, respectively. (b) Determination of ER-a binding sites on BRCA1: Various BRCA1-GST fusion proteins were constructed and prepared as indicated. 293T cells were transiently transfected with an ER-a cDNA construct. Cells were lysed in binding buffer and total cell lysates were prepared. Glutathione beads coupled with 10 mg of GST or GST-BRCA1 fusion proteins were incubated with 293T total cell lysates. Proteins bound to the beads were separated by SDS -PAGE and immunoblotted with anti-ER-a antibody. (c) Schematic diagram of ER-a constructs: The ER-a-AB domain includes the AF-1 domain, ER-a-CD domain includes the DNA binding domain (DBD), and ER-a-EF domain includes the AF-2 domain. ER-a-AD includes domains A -D while ER-a-CF includes domains C -F, as indicated. (d) Determination of BRCA1 binding sites on ER-a: ER-GST fusion proteins were generated as indicated in Figure 1c . Cells were transiently transfected with an HA-BRCA1 construct and total cell lysates were prepared. Glutathione beads coupled with 10 mg of GST or GST-ER-a fusion proteins were incubated with 293T cells transfected with HA-BRCA1 total cell lysates. Proteins bound to the beads were separated by SDS -PAGE and immunoblotted with anti-HA antibody
BRCA1 inhibits VEGF gene transcription via ER-a
Analysis of the cloned 3.4-Kb human VEGF gene promoter sequence revealed several consensus transcriptional response elements: AP-1, AP-2, GATA-6, 1-L-6RE, hypoxia-inducible enhancer sequences (Tischer et al., 1991; Garrido et al., 1993; Minchenko et al., 1994) and several half-palindromic but no classical estrogen response elements (EREs). The estrogen receptor (ER) complexes typically bind as a dimer to a consensus, 13-bp, palindromic ERE (Kumar and Chambon, 1988) . E 2 directly regulates VEGF gene transcription in endometrial cells and in Ishikama adenocarcinoma cells (Mueller et al., 2000) . Estradiolinduced gene transcription is ER-dependent and is activated through a variant ERE localized *1.5 Kb upstream from the VEGF transcription start site. To elucidate whether estrogen up-regulates VEGF gene transcription in breast cancer cells, VEGF transcriptional promoter activity in T47D breast cancer cells (ER-positive) transiently transfected with a luciferase fusion vector containing 3.4 Kb of 5' flanking DNA relative to the VEGF transcriptional start site was examined. Cells were treated with E 2 , lysed and then luciferase activity was measured and compared with the controls treated with ethanolic vehicle alone. Estrogen up-regulated VEGF promoter activity was about fourfold in the T47D cells (Figure 3a) .
BRCA1 was reported to inhibit ER activity in the presence of estrogen (Fan et al., 1999 (Fan et al., , 2001 ). However, the regulatory mechanism of VEGF gene transcription and VEGF protein secretion by BRCA1 is unknown. To determine whether BRCA1 inhibits VEGF gene transcription via ER-a in the presence of E 2 , we transiently transfected a human VEGF promoter-luciferase reporter construct and HA-BRCA1 into T47D cells. BRCA1 inhibited VEGF promoter activity in a dose-dependent manner in the presence of estrogen (Figure 3a ). The differences in the degree of inhibition of VEGF promoter activity by BRCA1 could not be attributed to differences in transfection efficiency, since cotransfection of the control plasmid pCMV-b-gal yielded similar b-galactosidase activities for all transfections.
ER-a/AF-2 activates VEGF gene transcription in the presence of estrogen and this effect is inhibited by BRCA1
To determine which ER-a domain is required for regulation of VEGF gene transcription, several deletion mutants of ER-a were constructed and analysed for their role in VEGF gene promoter activity. The constructs of ER-a fragments were designed (as shown in Figure 1c ) and were used for transfection into MDA-MB-231 cells, which are ER-a negative. When MDA-MB-231 cells were transfected with the fulllength ER-a cDNA construct, BRCA1 down-regulated VEGF gene transcription in the presence of E 2 ( Figure  3b ). Since ER-a contains two functional domains, AF-1 and AF-2, where AF-1 is located in the N-terminus of ER-a and is a ligand-independent transactivation domain, while AF-2 is located in the C-terminus of ER-a and is a hormone-inducible transcription activating function domain, we tested whether ER-a-CF, containing AF-2, or ER-a-AD containing AF-1, modulates VEGF promoter activity. We observed that ER-a-CF up-regulated VEGF promoter activity in the presence of estrogen (Figure 3c) , whereas ER-a-AD had no effect on VEGF promoter activity (Figure 3d) . Furthermore, in ER-a-CF transfected MDA-MB-231 cells, BRCA1 inhibited VEGF promoter activity in the presence of estrogen in a dose-dependent manner (Figure 3c) , suggesting that the AF-2 domain is required for BRCA1 regulation of VEGF gene transcription via ER-a.
BRCA1 inhibits VEGF secretion
We next analysed whether BRCA1 inhibits VEGF secretion from breast cancer cells. T47D cells were Figure 2 Endogenous interaction of BRCA1 with ER-a in 293T, MCF-10A and MCF-7 cells: Cells were unstimulated or stimulated with b-estradiol (E 2 (100 nM)) for 30 min. Total cell lysates were prepared and immunoprecipitated with either control IgG or ER-a antibody. The immunoprecipitates were resolved by SDS -PAGE and analysed by Western blotting using anti-BRCA1 (HA) or anti-ER-a antibodies, as indicated. IP: Immunoprecipitation; WB: Western blotting transiently transfected with BRCA1 and analysed for VEGF secretion by ELISA assay. As shown in Figure  4a , in the presence of E 2 , BRCA1 inhibited VEGF secretion levels.
The N-terminal domain of BRCA1 is essential for downregulating VEGF gene transcription activation
To determine further the role of the N-and C-terminal domains of BRCA1 in regulating VEGF gene transcriptional activation, we analysed the effects of BRCA1 fragments (1 -683 a.a., 304 -683 a.a., 1301 -1863 a.a.) on the regulation of VEGF promoter activity. T47D cells were transiently transfected with wt-BRCA1 or truncated BRCA1 constructs. In the presence of estrogen, wt-BRCA1 and BRCA1 (1 -683) amino residues suppressed VEGF promoter activity (Figure 4b ). However, a truncated BRCA1 fragment containing 1301 -1863 amino acid residues also partially inhibited VEGF promoter activity. These data indicate that the N-terminus of BRCA1 is essential for binding to ER-a and for down-regulating VEGF transcription via the estrogen signaling pathway, while the carboxyl-terminal portion of BRCA1 was also able to partially suppress VEGF promoter activity.
Effects of mutated BRCA1 on VEGF gene transcription and secretion
We next tested whether BRCA1 mutants effect VEGF gene transcription via ER-a. To determine whether . pCMVb-gal and pcDNA3 vectors were also included for normalization of the transfections. After recovery overnight, cells were treated with ethanolic vehicle (control) or E 2 (100 nM) for 16 h. Cells were assayed for luciferase and b-galactosidase activities after 48 h. The expression of luciferase from the VEGF-Luc promoter was analysed by using a luciferase assay kit. Luciferase measurements were made using 40 ml of cell lysates and are presented as the mean+s.e. of the fold activation as compared with the control vector. Each experiment was performed at least three times in triplicate. (c -d) MDA-MB-231 cells were transfected with the VEGF promoter reporter plasmid (VEGF-Luc) in combination with the ER-CF domain (c) or ER-AD domain (d) and various concentrations of HA-BRCA1. Luciferase activity was determined as described above Regulation of VEGF by BRCA1 and estrogen receptor H Kawai et al mutations in the BRCA1 C-terminal domain bind to ER-a and modulate VEGF gene transcription, several BRCA1 mutants were constructed (A1708E, M1775R and Y1853X) and were analysed for their interaction with ER-a. These mutations were found in several cases of hereditary breast cancer. As shown in Figure  5a , the BRCA1 mutant Y1853X failed to interact with ER-a. Similar data were obtained with the BRCA1 mutants A1708E and M1775R (data not shown). These BRCA1 mutants also failed to inhibit VEGF transcription activation in the presence of estrogen (Figure 5b ). To further elucidate the potential role of mutated BRCA1 in VEGF secretion, we transfected T47D cells with BRCA1 mutants and analysed their effects on VEGF secretion. As shown in Figure 5c , these BRCA1 mutants failed to inhibit E 2 -induced VEGF secretion, and only wild-type BRCA1 could rescue the inhibition of VEGF. To further investigate the function of wild-type BRCA1 in inhibiting VEGF secretion, we transfected ER-a and the wild-type BRCA1 cDNA construct into HCC-1937 breast cancer cells, which have a single mutant BRCA1 allele (5382 ins C) and thus lack endogenous functional BRCA1 (Tomlinson et al., 1998) . As shown in Figure 5d , E 2 -induced VEGF secretion was significantly reduced in HCC-1937 cells in the presence of wild-type BRCA1. Taken together, these data indicate that mutations in BRCA1 impaired the regulation of VEGF gene transcription and secretion, and suggest that functional inactivation of BRCA1 by point mutations could promote tumorigenesis through hormonal regulation of mammary epithelial cell proliferation.
Discussion
BRCA1 was shown to inhibit the ligand-dependent transcription activity of ER-a through a direct interaction between the two proteins (Fan et al., 1999 (Fan et al., , 2001 . Recent studies also indicate that BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor (Mueller et al., 2000) . In this report, we describe a role for BRCA1 and estrogen in the regulation of VEGF gene transcription and secretion in breast cancer cells. VEGF is an important angiogenic molecule that is regulated by estrogen in vivo in primary cultures derived from the reproductive tract in endometrial cancer cell lines, and in breast cancer cells (Folkman, 1995; Battegay, 1995; Ferrara, 1999; Weidner and Folkman, 1996; Kim et al., 1992; Brown et al., 1995; Levine et al., 1998; Santin et al., 1999; Guidi et al., 1995; Gasparini, 1997) . In addition to stimulating the growth of new capillaries from existing vessels, VEGF is also the most potent known regulator of capillary permeability, and a prognostic factor for many tumors including those of endocrine-responsive tissues such as the breast. Our results demonstrate that BRCA1 and ER-a modulate VEGF gene transcription and VEGF protein secretion in breast cancer cells. ER-a interacts specifically with BRCA1 in vitro and in vivo. This binding is mediated via the AF-2 domain of ER-a and the amino-acid residues 1 -306 and 428 -683 of BRCA1. Endogenous interaction of BRCA1 with ER-a was observed in MCF-10A breast epithelial cells and in MCF-7 breast cancer cells. However, in the presence of E 2 , the interaction of ER-a with BRCA1 (7) or with E 2 (100 nM) for 16 h and then assayed for luciferase and b-galactosidase activities after 48 h Regulation of VEGF by BRCA1 and estrogen receptor H Kawai et al was significantly decreased, indicating that stimulation of breast cancer cells with estrogen disrupts the endogenous complex of ER-a with BRCA1. Furthermore, our results indicated that BRCA1 inhibited VEGF promoter activity and VEGF protein secretion in breast cancer cells in a dose-dependent manner in the presence of estrogen. Interestingly, mutated forms of BRCA1 that have been identified in familial breast cancers failed to associate with ER-a and did not suppress VEGF promoter activity and secretion, in contrast to the observations with wild-type BRCA1. These findings suggest a potential role of BRCA1 in the proliferative control of normal estrogen-regulated tissues and a potential basis by which its mutational inactivation could promote tumorigenesis and angiogenesis through inappropriate hormonal responses.
In this study, we demonstrated that BRCA1 suppressed VEGF promoter activity through ER-a. The molecular mechanism of VEGF transcription regulation by ER is by the direct binding of ER-a Figure 5 (a) ER-a interacts with mutated and wild-type BRCA1: 293T cells were transfected with the expression vectors for either wt-HA-BRCA1 (0.5 mg) or mutated BRCA1 (Y1853X). Total cell lysates were prepared and immunoprecipitated with anti-ER-a antibody. The immunoprecipitates were separated by SDS -PAGE and immunoblotted with anti-HA antibody. Aliquots of each lysate were analysed by Western blot analysis for expression of ER-a and of HA-tagged wild-type and mutated BRCA1, as indicated. (b) 293T cells were transfected with VEGF-Luc, ER-a and wt-HA-BRCA1 or mutant HA-BRCA1 (A1708E, Y1853X or M1775R) as indicated. After recovery, cells were treated with E 2 (100 nM) or ethanolic vehicle (7). pCMVb-gal and pcDNA3 vectors were also included for normalization of the transfections. Forty-eight hours after transfection, luciferase activity was analysed by using a luciferase assay kit. The data are presented as the mean+s.d. of four independent experiments performed in triplicate. (c) VEGF secretion assay in T47D breast cancer cells transiently transfected with BRCA1 mutants: T47D cells were transiently transfected with mutated BRCA1 cDNA constructs (A1708E, M1775R and Y1853X). After 48 h, cells were treated with 17-b estradiol (E 2 , 100 nM) or control ethanolic vehicle (7) for 18 h. The supernatants were then collected and analysed for VEGF protein secretion by specific ELISA for VEGF. (d) VEGF secretion assay in HCC-1937 breast cancer cells transiently transfected with ER-a and wild-type BRCA1 (HA-BRCA1): Cells were analysed for VEGF secretion as described above in (c) to the estrogen response element (ERE) in the VEGF promoter region. In the presence of estrogen, ER-a up-regulates VEGF promoter activity about fourfold as compared to the control (Figure 3 ). The AF-2 but not the AF-1 domain of ER-a is associated with VEGF gene transcription. The interaction of BRCA1 and ER-a is down-regulated in the presence of E 2 , leading to the suppression of VEGF transcription activation. BRCA1 was reported to inhibit ER-a activity in the presence of estrogen (Fan et al., 1999 (Fan et al., , 2001 , suggesting that BRCA1 may regulate the growth of breast cancer by down-regulating the estrogen signaling pathway. The N-terminal domain (1 -300) of BRCA1 directly binds to the AF-2 domain of ER-a (Fan et al., 2001) . However, as detailed here, we observed a second domain of BRCA1 (428 -683) that also interacts with ER-a. Our studies and those by Fan et al. (2001) showed the endogenous interaction of BRCA1 with ER-a. While Fan et al. (2001) did not observe any effects of estrogen on this interaction, we observed that stimulation of normal breast epithelial cells (MCF-10A) and MCF-7 breast cancer cells with estrogen for 30 min disrupted the complex of ER-a and BRCA1, leading to a significant decrease in the ER-a-BRCA1 interaction. These differences could be due to different conditions for stimulation of cells (30 min versus 24 h) and ligand concentration (E 2 : 100 nM versus 1 mM). Regardless, both of our studies also showed that the N-terminal domain of BRCA1 interacts with the AF-2 domain of ER-a. Our novel data demonstrate that the functional binding of the N-terminal domain of BRCA1 to the AF-2 domain of ER-a leads to the down-regulation of VEGF gene transcription and VEGF protein secretion from breast tumor cells. Interestingly, as shown in our study, the BRCA1 domain (1301 -1863) also inhibited VEGF gene transcription activation and VEGF secretion. This suggests that inhibition of VEGF activity requires the binding of BRCA1 to ER-a via the N-terminus of BRCA1 and the recruitment of corepressors via the C-terminus of BRCA1. The finding that BRCA1 can function similar to estrogendependent ER-a to down-regulate the transcription activation of VEGF suggests the potential involvement of BRCA1 in the proliferative control of normal estrogen-regulated tissues.
In addition, our results showed that BRCA1 mutants were defective in their ability to bind to ER-a and to suppress VEGF gene transcription activity in breast cancer cells ( Figure 5 ). The failure of mutant forms of BRCA1 to inhibit VEGF activity may contribute to the development of breast cancer. A transcriptional inhibitory function for the carboxyl terminal of BRCA1 has been suggested by the findings that this region of BRCA1 is capable of binding to the components of transcription complexes, including the Rb protein, Rb-associated proteins (Rb Ap46 and Rb Ap48), histone deacetylases (HDACs) and the carboxyl-terminal interacting protein (CtIP). It has been shown that breast cancerassociated mutations of BRCA1 abolish its ability to inhibit ER-a activity, and that domains within the amino and carboxyl-terminal of the BRCA1 protein are required for the inhibition (Fan et al., 2001) . Moreover, BRCA1 inhibition of ER-a activity was demonstrated under conditions in which a BRCA1 transgene was transiently or stably over-expressed in cell lines with endogenous wild-type BRCA1 and in breast cancer cell lines that lack endogenous functional BRCA1 (HCC-1937) . Thus, mutational inactivation of BRCA1 could result in the persistent expression of estrogen-responsive genes leading to inappropriate hormonal responses which might promote the proliferation and transformation of epithelial cells.
In conclusion, BRCA1 inhibits VEGF gene transcription activation and VEGF protein secretion through the estrogen signaling pathway. This mechanism involves the direct interaction of BRCA1 and ER-a, which is regulated by estrogen. In addition, mutated BRCA1 failed to associate with ER-a and to suppress VEGF promoter activity and VEGF secretion, suggesting a novel pathogenic mechanism whereby mutations in BRCA1, via their interaction with ER-a, could promote tumorigenesis and angiogenesis.
Materials and methods
Cell lines
The ER-positive human breast cancer cell lines T47D and MCF-7, the ER-negative HCC-1937 cells and normal MCF-10A breast epithelial cells were obtained from the ATCC (American Type Culture Collection, Rockville, MD, USA) and grown in RPMI-1640 supplemented with 10% FBS, penicillin (100 units/ml), streptomycin (100 mg/ml) and insulin (7 mg/ml). The ER-negative human breast cancer cell line MDA-MB-231, and human embryonic kidney cell line 293T (expressing simian virus 40T antigen), were maintained in DMEM supplemented with 10% FBS, penicillin (100 units/ ml), and streptomycin (100 mg/ml).
Immunoprecipitation (IP) and Western blotting
Cells were stimulated with ethanolic vehicle (control) or E 2 (100 nM) for 30 min, as indicated, harvested and lysed in IP buffer (0.5% NP-40 solution: 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 10% glycerol, and protease inhibitors). Total cell lysates were incubated with protein G beads with normal IgG as a pretreatment. The supernatants were then treated with each antibody as indicated and immunoprecipitated with protein G beads for 3 h. After immunoprecipitation, beads were extensively washed four times. Laemmli buffer was added, and the samples were loaded onto 6 -10% SDS -PAGE gel, and transferred to nitrocellulose membrane (Millipore). Immunoblot analysis was performed using primary antibodies. The primary antibodies were as follows: ER-a (HC-20, rabbit polyclonal, Santa Cruz), BRCA1 (C-20, rabbit polyclonal, Santa Cruz), HA-probe (F-7, mouse monoclonal, Santa Cruz). Immunodetection was performed using the enhanced chemiluminescence system (ECL, Amersham).
GST binding assays
To prepare GST-BRCA1 fusion proteins, BRCA1 fragments generated by PCR were cloned into the vector pGEX-2T (Amersham Pharmacia Biotech) between sites BamHI and EcoRI. To prepare GST-ER-a fusion proteins, ER-a fragments generated by PCR were also cloned into the vector pGEX-4T-1 (Amersham Pharmacia Biotech) between sites EcoRI and XhoI. GST fusion proteins were produced by 1 mM isopropyl b-thiogalactopyranoside (IPTG) induction, purified on a large scale by affinity chromatography with glutathione-Sepharose beads, and then protein concentration was estimated. The cells were transiently transfected with each vector as indicated, then harvested and lysed as described above. The lysates were incubated with GST (control) or GST fusion protein for 2 h at 48C. Beads were extensively washed four times with IP buffer, eluted in Laemmli buffer, loaded onto 6 -10% SDS -PAGE gel, and analysed using autoradiography.
Transient transfection assay
Cells were maintained at 50% confluence in 6-well plates and transiently transfected with each vector using LipofectAmine (GIBCO BRL). The total DNA transfected in cells was kept constant by the addition of empty control vector. After 3 h incubation, the medium was changed to medium containing serum. After recovery, cells were lysed and analysed by immunoprecipitation and Western blot analysis as indicated.
Assay of VEGF gene transcriptional activity
Breast cancer cell lines (T47D, MDA-MB-231) were transiently transfected with reporter plasmid VEGF-Luc. Co-transfection of HA-BRCA1, BRCA1 fragment, or BRCA1 mutant was performed as indicated. The pCMV-bgal was also co-transfected to normalize luciferase values by measuring b-galactosidase activity in the same sample. After recovery from transfection, the medium was changed to phenol-red, serum-free DMEM. The cells were starved for 8 h, stimulated with ethanolic vehicle (control) or E 2 (100 nM for 16 h, harvested and analysed using luciferase assays.
VEGF secretion assay
T47D or HCC-1937 cells were transiently transfected with either HA-BRCA1 (wt-BRCA1) and mutated BRCA1 or with ER-a and HA-BRCA1, respectively, followed by medium change to phenol-red, serum-free DMEM. Cells were stimulated with ethanolic vehicle (control) or E 2 (100 nM) for 16 h and the supernatants were collected for the VEGF secretion assay by ELISA. VEGF secretion levels were measured using a Quantikine human VEGF immunoassay (R&D Diagnostics, Minneapolis, MN, USA). The values were normalized to the total protein concentration in each dish.
